EnteroBiotix, a clinical-stage biopharmaceutical company pioneering microbiome therapies, has announced that its Phase 2a MAST trial has successfully completed enrollment of 50 adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) for specific blood cancers. 

 

Participants will receive either EBX-102-02 or a matched placebo before conditioning chemotherapy and will be monitored for 12 months post-transplant.

 

The investigator-initiated study is sponsored by Imperial College London and funded by the Medical Research Council (MRC). Led by Co-Chief Investigators Professor Julian Marchesi and Dr Jiri Pavlu, the trial brings together haematologists from leading UK transplant centers, with EnteroBiotix supplying EBX-102-02 for the study.

 

Profound disruption of the gut microbiome is a common challenge during allo-HSCT, and loss of microbial diversity has been linked to higher infection rates, graft-versus-host disease (GVHD), and reduced survival. 

 

The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation. Exploratory outcomes will evaluate broader clinical transplant results. Topline data are expected in the first half of 2027.

 

“Profound disruption of the intestinal microbiome is common during allogeneic stem cell transplantation and has been strongly associated with adverse outcomes,” said Professor Julian Marchesi. 

 

“MAST builds on prior promising work from the Imperial team utilising traditional FMT approaches and has been designed to assess whether pre-emptive microbiota restoration using EBX-102-02 can preserve microbiome diversity during the transplant period and potentially improve post-transplant outcomes. We are pleased to have completed enrolment and thank the patients and clinical teams involved.”

 

Dr James McIlroy, Chief Executive Officer of EnteroBiotix, added: “Completion of enrolment in MAST builds on our recent progress in IBS and cirrhosis and marks another step in evaluating the potential of EBX-102-02 across multiple indications with high unmet medical need. We are excited about the potential of our platform and technology for supporting the treatment of oncology patients. We thank the Imperial investigators for their collaboration and look forward to topline data in H1 2027.”